AlzeCure Pharma AB (publ) (ALZCUR.ST)
- Previous Close
2.5100 - Open
2.6800 - Bid 2.4700 x --
- Ask 2.5100 x --
- Day's Range
2.3400 - 2.6800 - 52 Week Range
0.8120 - 3.8600 - Volume
38,639 - Avg. Volume
148,959 - Market Cap (intraday)
222.504M - Beta (5Y Monthly) 0.29
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4100 - Earnings Date May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.20
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.
www.alzecurepharma.seRecent News: ALZCUR.ST
View More
Performance Overview: ALZCUR.ST
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALZCUR.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALZCUR.ST
View MoreValuation Measures
Market Cap
221.62M
Enterprise Value
200.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
13.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-96.02%
Return on Equity (ttm)
-236.55%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-35.54M
Diluted EPS (ttm)
-0.4100
Balance Sheet and Cash Flow
Total Cash (mrq)
20.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-23.1M